Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors: International Journal of Antimicrobial Agents

G Sterrantino, V Borghi, AP Callegaro, B Bruzzone, F Saladini, F Maggiolo, G Maffongelli, M Andreoni, M De Gennaro, N Gianotti, P Bagnarelli, A Vergori, A Antinori, M Zazzi, M Zaccarelli, on behalf of the ARCA Study Group

Research output: Contribution to journalArticle

Abstract

This study investigated the prevalence of doravirine (DOR) resistance mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced patients. DOR resistance was assessed in samples from NNRTI-experienced patients who underwent genotypic testing for virological failure from the Antiretroviral Response Cohort Analysis (ARCA) database. Intermediate DOR resistance was defined as detection of any of V106A/M, Y188C/H, V108I, and K103N+P225H. High-level DOR resistance was defined as detection of any of Y188L, M230L, G190E, V106A/M+F227L, and V106A/M+L234I. Overall, 6893 patients were included in the study: 64.2% had experienced efavirenz (EFV), 54.4% nevirapine (NVP), 6.8% etravirine (ETR), 7.7% rilpivirine (RPV) and 0.7% delavirdine. Among NNRTI-experienced patients, 12.7% and 6.1% of subjects had intermediate and high-level DOR resistance, respectively. The most common DOR resistance mutation was Y188L. In multivariable analysis, previous EFV use (OR = 1.52, 95% CI 1.15–2.02) and ETR use (OR = 1.91, 95% CI 1.34–2.73) were associated with detection of high-level DOR resistance, whilst RPV use was associated with a lower probability of high-level DOR resistance (OR = 0.39, 95% CI 0.22–0.71). Moreover, EFV use (OR = 1.76, 95% CI 1.19–2.58) and ETR use (OR = 1.72, 95% CI 1.10–2.68) were associated with detection of the Y188L mutation, whereas RPV use was not (OR = 0.16, 95% CI 0.05–0.50). In Italy, DOR resistance is uncommon among NNRTI-experienced patients, confirming a distinguishing resistance pattern within NNRTIs. However, previous EFV and ETR experience poses a higher risk of DOR resistance. These results support the use of DOR in NNRTI-experienced patients. © 2019 Elsevier B.V. and International Society of Chemotherapy
Original languageEnglish
Pages (from-to)515-519
Number of pages5
JournalInternational Journal of Antimicrobial Agents
Volume53
Issue number4
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors: International Journal of Antimicrobial Agents'. Together they form a unique fingerprint.

  • Cite this

    Sterrantino, G., Borghi, V., Callegaro, AP., Bruzzone, B., Saladini, F., Maggiolo, F., Maffongelli, G., Andreoni, M., De Gennaro, M., Gianotti, N., Bagnarelli, P., Vergori, A., Antinori, A., Zazzi, M., Zaccarelli, M., & Group, O. B. O. T. ARCA. S. (2019). Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors: International Journal of Antimicrobial Agents. International Journal of Antimicrobial Agents, 53(4), 515-519. https://doi.org/10.1016/j.ijantimicag.2019.02.007